Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.MILLIPLEX® Human Immuno-Oncology Checkpoint Protein Panel 2 is a 31-plex kit to be used for the simultaneous quantification of any or all of the following analytes in serum, plasma and tissue culture samples: 4-1BBL/TNFSF9, 5′-NT/CD73 (5′-nucleotidase), APRIL (TNFSF13), Arginase-1, B7-H2/ICOSL (Inducible T cell costimulator ligand), B7-H3/CD276, B7-H4/VTCN1 (V-set domain-containing T-cell activation inhibitor 1), B7-H5/VISTA (V-set immunoregulatory receptor), B7-H6 (Natural killer cell cytotoxicity receptor 3 ligand), BAFF/BLyS (TNFSF13B), CD25/IL-2Rα (Interleukin-2 receptor alpha), CD30/TNFRSF8, CD40L (CD40 ligand), CD137/4-1BB (TNFRSF9), CD226/DNAM-1 (DNAX accessory molecule 1), E-Cadherin, FGL1/Hepassocin (Fibrinogen-like protein 1), Galectin-1 (Gal-1), Galectin-3 (Gal-3), Granulysin, Granzyme B, IDO1 (Indoleamine 2,3-dioxygenase 1), MICA (MHC class I polypeptide-related sequence A), MICB (MHC class I polypeptide-related sequence B), Nectin-2 (PVRL2, CD112), Nectin-4 (PVRL4), OX40/CD134 (TNFRSF4), Perforin, PVR/CD155 (Poliovirus receptor cell adhesion molecule), Siglec-7 (Sialic acid-binding Ig-like lectin 7, CD328), Siglec-9 (Sialic acid-binding Ig-like lectin 9, CD329).
The Human Immuno-Oncology Checkpoint Protein Panel 2 bead-based multiplex panel, using the Luminex® xMAP technology, enables the simultaneous analysis of 31 immune checkpoint proteins in human serum, plasma and cell culture samples.This is an overnight incubation assay (16-18 hours at 2-8°C).A maximum of 25 μL per well 1:2 diluted serum or plasma can be used. Tissue culture or other media may be run neat or appropriately diluted in control medium. Note: Best results using cell/tissue lysate samples may require diluting in assay buffer while testing similarly diluted lysis buffer for matrix effects.CD40 Ligand;4-1BBL/TNFSF9;Arginase-1;B7-H2/ICOSL;B7-H3/CD276;5′-NT/CD73;B7-H4/VTCN1;APRIL/TNFSF13;B7-H5/VISTA;CD25/IL-2Rα;B7-H6;CD137/4-1BB;Granzyme B;CD226/DNAM-1;CD30/TNFRSF8;E-Cadherin;FGL1/Hepassocin;Galectin-1 (GAL1);Galectin-3;Granulysin;IDO1;MICA;MICB;Nectin-2;BAFF/Blys;Nectin-4;OX40/CD134;PVR/CD155;Siglec-7;Siglec-9;Perforin
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.